Clinical Trial Search

Primary: Yearly Progression Rate of Atrophic Lesions Using Fundus Autofluorescence (FAF) Images — 0.35; 0.64 mm^2/year

Primary: Mean Rate of Change in Total Area of Macular Atrophy, as Measured by Fundus Autofluorescence (FAF) — 1.280; 1.309 Rate of change from BL (mm^2/yr)

Primary: Change in Electrical Response of the Retina to a Flash of Light, as Measured by Electroretinogram — -12.23; 68.00; 96.69 percent suppression

Primary: Mean Rate of Change in the Area of Ellipsoid Zone Defect From Baseline Through Month 18 — 0.6383; 0.6644 mm^2/18 months — p=0.8669

Primary: Rate of LOSS of 31 Hertz Cone Electroretinographic Function — 0.028; 0.022 log microvolts/year — p=0.30

Primary: Change in Visual Acuity (VA) in Participant's Study Eye — -2.8; -5.9; -8.6; -10.3 Letters read

Primary: Macular Pigment Optical Density — 0.48; 0.38; 0.42 Density units of Macular Pigment (du)

Primary: Change in Skin Carotenoid Status in Response to Genetic Risk Disclosure as Measured by Reflectance Spectroscopy — 257.7; 290.9 Reflection units (RU)

Primary: Overall Safety of Adeno-Associated Virus Vector (AAV-OPTIRPE65) - Number of Participants With a Safety Event — 0; 0; 1; 0 Participants

Primary: Change in Dark Adaptation Rod Intercept Time (RIT) From Baseline in the Study Eye at the Treatment Completion Visit (Month 2 for Cohort 1 and Month 1 for Cohort 2)…

Primary: Number of Participants Who Had Positive Genetic Test Results — 4 Participants

Primary: Mean Change in Cone Spacing in Arcminutes (Z Score) of 2 Baseline Values Were Compared With Measurements Obtained at Post-op Month 36 — 1.13; 0.85 Difference in change…

Primary: Proportion of Patients by Type of IRD — 720; 174; 30; 58 Participants

Primary: Change in Dark Adaptation Rod Intercept Time (RIT) From Baseline in the Study Eye at the Treatment Completion Visit (Month 2 for Cohort 1 and Month 1 for Cohort 2)…

Primary: The Change in Best-corrected Visual Acuity (BCVA) From Baseline to Year 2 for All Participants. — 0.2; -11.3 ETDRS Letters

Primary: Targeted Vision Function (TVF) — 2.18; 2.14 units on a scale — p=.47

Primary: Change in High Contrast Visual Acuity — 5.5; 0 Number of Letters Read on a Vision Board

Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 6 Weeks Following Administration, at Least Possibly Related to…

Primary: Development of Advanced AMD in People at Moderate to High Risk for Progression. — 493; 468; 507; 472 Eyes — p=<0.013

Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 6 Weeks Following Administration, at Least Possibly Related to…

Primary: Change From Baseline in the Area of Geographic Atrophy (GA) Assessed by Color Fundus Photographs (FP) in the Study Eye — -0.52; -0.94; -0.99; -0.96 square millimeter (m^2)

Primary: Changes of Macular Pigment Optical Density (MPOD) During 48 Weeks and 2 Years — 0.315; 0.307; 0.315; 0.320 density units — p=<0.05

Primary: Rate of Change in Area of Geographic Atrophy (GA), Based on Masked, Digital Grading of Fundus Photography by an External Reading Center, in the Study Eye at 12 Months…

Primary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants

Primary: Anatomic Response

Primary: Change in Best Corrected Visual Acuity From Baseline — 3.0 Letters

Primary: Spleen Volume — 2324.0; 2120.0; 778.0; 1707.7 mL

Primary: Number of Treatment-emergent Adverse Events. — 6 Participants

Primary: Number of Participants Experiencing Ocular or Non-ocular Adverse Events — 6; 6 participants

Primary: LL BCVA Score Change From Baseline — 0.7; -0.6; 1.1; -0.8 Letters